Comparison of the real-world safety of two different long-acting methylphenidate formulations (Medikinet^® MR and Concerta^®) – a Danish nationwide register-based cohort study

1. Ayano G, Demelash S, Gizachew Y, Tsegay L, Alati R. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses. J Affect Disord. 2023;339:860–6. AyanoG DemelashS GizachewY TsegayL AlatiR The global prevalence of attention deficit hyperactivity disorder in children and adolescents: An umbrella review of meta-analyses J Affect Disord 2023 339 860 6 Search in Google Scholar

2. Ayano G, Tsegay L, Gizachew Y, Necho M, Yohannes K, Abraha M, et al. Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe. Psychiatry Res. 2023;328:115449. AyanoG TsegayL GizachewY NechoM YohannesK AbrahaM Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe Psychiatry Res 2023 328 115449 Search in Google Scholar

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC. : American Psychiatric Association; 2013. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 5th ed. Washington, DC. American Psychiatric Association 2013 Search in Google Scholar

4. Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. WolraichML HaganJF AllanC ChanE DavisonD EarlsM Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents Pediatrics 2019 144 4 e20192528 Search in Google Scholar

5. CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020. CADDRA Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition Toronto ON CADDRA 2020 Search in Google Scholar

6. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2018 [Available from: nice.org.uk/guidance/ng87]. NICE Attention deficit hyperactivity disorder: diagnosis and management NICE guideline [NG87] 2018 [Available from: nice.org.uk/guidance/ng87]. Search in Google Scholar

7. Gimbach S, Vogel D, Fried R, Faraone SV, Banaschewski T, Buitelaar J, et al. The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions. Eur Neuropsychopharmacol. 2023;73:24–35. GimbachS VogelD FriedR FaraoneSV BanaschewskiT BuitelaarJ The impact of the COVID-19 pandemic on ADHD medicine consumption in 47 countries and regions Eur Neuropsychopharmacol 2023 73 24 35 Search in Google Scholar

8. Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, Schuiling-Veninga CCM, et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005–2012. Eur Neuropsychopharmacol. 2017;27(5):484–93. BachmannCJ WijlaarsLP KalverdijkLJ BurcuM GlaeskeG Schuiling-VeningaCCM Trends in ADHD medication use in children and adolescents in five western countries, 2005–2012 Eur Neuropsychopharmacol 2017 27 5 484 93 Search in Google Scholar

9. Karlstad O, Zoega H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol. 2016;72(12):1507–14. KarlstadO ZoegaH FuruK BahmanyarS MartikainenJE KielerH Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries Eur J Clin Pharmacol 2016 72 12 1507 14 Search in Google Scholar

10. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17–37. GrahamJ BanaschewskiT BuitelaarJ CoghillD DanckaertsM DittmannRW European guidelines on managing adverse effects of medication for ADHD Eur Child Adolesc Psychiatry 2011 20 1 17 37 Search in Google Scholar

11. Ching C, Eslick GD, Poulton AS. Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. JAMA Pediatr. 2019;173(7):630–9. ChingC EslickGD PoultonAS Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis JAMA Pediatr 2019 173 7 630 9 Search in Google Scholar

12. Storebo OJ, Storm MRO, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2023;3(3):CD009885. StoreboOJ StormMRO Pereira RibeiroJ SkoogM GrothC CallesenHE Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) Cochrane Database Syst Rev 2023 3 3 CD009885 Search in Google Scholar

13. Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC Psychiatry. 2013;13:237. CoghillD BanaschewskiT ZuddasA PelazA GaglianoA DoepfnerM Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies BMC Psychiatry 2013 13 237 Search in Google Scholar

14. MEDICE. Medikinet retard SmPC. 2023. MEDICE Medikinet retard SmPC 2023 Search in Google Scholar

15. Garcia-Garcia P, Lopez-Munoz F, Molina JD, Fischer R, Alamo C. Methylphenidate Extended-Release Capsules: A New Formulation for Attention-Deficit Hyperactivity Disorder. Front Drug Des Discovery. 2009;4:228–46. Garcia-GarciaP Lopez-MunozF MolinaJD FischerR AlamoC Methylphenidate Extended-Release Capsules: A New Formulation for Attention-Deficit Hyperactivity Disorder Front Drug Des Discovery 2009 4 228 46 Search in Google Scholar

16. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–95. BanaschewskiT CoghillD SantoshP ZuddasA AshersonP BuitelaarJ Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline Eur Child Adolesc Psychiatry 2006 15 476 95 Search in Google Scholar

17. Dopfner M, Ose C, Fischer R, Ammer R, Scherag A. Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet((R)) retard and Concerta((R))--a randomized, controlled, double-blind multicenter clinical crossover trial. J Child Adolesc Psychopharmacol. 2011;21(5):445–54. DopfnerM OseC FischerR AmmerR ScheragA Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention-deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet((R)) retard and Concerta((R))--a randomized, controlled, double-blind multicenter clinical crossover trial J Child Adolesc Psychopharmacol 2011 21 5 445 54 Search in Google Scholar

18. Cikili Uytun M, Çetin FH, Babadağı Z. Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey. Psychiatry and Clinical Psychopharmacology. 2019;29(4):722–9. Cikili UytunM ÇetinFH BabadağıZ Parent-reported social problems and clinician-evaluated adverse effects may be differentially affected by differing extended release methylphenidate formulations: a prospective, naturalistic study from Turkey Psychiatry and Clinical Psychopharmacology 2019 29 4 722 9 Search in Google Scholar

19. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22–5. PedersenCB The Danish Civil Registration System Scand J Public Health 2011 39 7 Suppl 22 5 Search in Google Scholar

20. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90. SchmidtM SchmidtSA SandegaardJL EhrensteinV PedersenL SorensenHT The Danish National Patient Registry: a review of content, data quality, and research potential Clin Epidemiol 2015 7 449 90 Search in Google Scholar

21. Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data Resource Profile: The Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798-f. PottegardA SchmidtSAJ Wallach-KildemoesH SorensenHT HallasJ SchmidtM Data Resource Profile: The Danish National Prescription Registry Int J Epidemiol 2017 46 3 798-f Search in Google Scholar

22. van Stralen JP. The clinical impact of switching attention deficit hyperactivity disorder patients from OROS((R))-MPH to Novo-MPH ER-C((R)): A paediatric practice review. Paediatr Child Health. 2013;18(2):70–3. van StralenJP The clinical impact of switching attention deficit hyperactivity disorder patients from OROS((R))-MPH to Novo-MPH ER-C((R)): A paediatric practice review Paediatr Child Health 2013 18 2 70 3 Search in Google Scholar

23. Fallu A, Dabouz F, Furtado M, Anand L, Katzman MA. A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA((R))) and generic novo-methylphenidate ER-C (NOVO-generic). Ther Adv Psychopharmacol. 2016;6(4):237–51. FalluA DabouzF FurtadoM AnandL KatzmanMA A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA((R))) and generic novo-methylphenidate ER-C (NOVO-generic) Ther Adv Psychopharmacol 2016 6 4 237 51 Search in Google Scholar

24. Man KKC, Hage A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry. 2023;10(5):323–33. ManKKC HageA BanaschewskiT InglisSK BuitelaarJ CarucciS Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study Lancet Psychiatry 2023 10 5 323 33 Search in Google Scholar

25. Krinzinger H, Hall CL, Groom MJ, Ansari MT, Banaschewski T, Buitelaar JK, et al. Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence. Neurosci Biobehav Rev. 2019;107:945–68. KrinzingerH HallCL GroomMJ AnsariMT BanaschewskiT BuitelaarJK Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence Neurosci Biobehav Rev 2019 107 945 68 Search in Google Scholar

26. Lee MJ, Yang KC, Shyu YC, Yuan SS, Yang CJ, Lee SY, et al. Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan. J Affect Disord. 2016;189:110–7. LeeMJ YangKC ShyuYC YuanSS YangCJ LeeSY Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan J Affect Disord 2016 189 110 7 Search in Google Scholar

27. Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, et al. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry. CNS Drugs. 2015;29(10):865–77. CorteseS PaneiP ArcieriR GerminarioEA CapuanoA MargariL Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry CNS Drugs 2015 29 10 865 77 Search in Google Scholar

28. Park J, Lee DY, Kim C, Lee YH, Yang SJ, Lee S, et al. Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea. Child Adolesc Psychiatry Ment Health. 2022;16(1):80. ParkJ LeeDY KimC LeeYH YangSJ LeeS Long-term methylphenidate use for children and adolescents with attention deficit hyperactivity disorder and risk for depression, conduct disorder, and psychotic disorder: a nationwide longitudinal cohort study in South Korea Child Adolesc Psychiatry Ment Health 2022 16 1 80 Search in Google Scholar

29. Ramstad E, Storebo OJ, Gerner T, Krogh HB, Holmskov M, Magnusson FL, et al. Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis(). Scand J Child Adolesc Psychiatr Psychol. 2018;6(1):52–71. RamstadE StoreboOJ GernerT KroghHB HolmskovM MagnussonFL Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis() Scand J Child Adolesc Psychiatr Psychol 2018 6 1 52 71 Search in Google Scholar

30. Liang SH, Yang YH, Kuo TY, Liao YT, Lin TC, Lee Y, et al. Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study. Res Dev Disabil. 2018;72:96–105. LiangSH YangYH KuoTY LiaoYT LinTC LeeY Suicide risk reduction in youths with attention-deficit/hyperactivity disorder prescribed methylphenidate: A Taiwan nationwide population-based cohort study Res Dev Disabil 2018 72 96 105 Search in Google Scholar

31. Huang KL, Wei HT, Hsu JW, Bai YM, Su TP, Li CT, et al. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study. Br J Psychiatry. 2018;212(4):234–8. HuangKL WeiHT HsuJW BaiYM SuTP LiCT Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study Br J Psychiatry 2018 212 4 234 8 Search in Google Scholar

32. Liang EF, Lim SZ, Tam WW, Ho CS, Zhang MW, McIntyre RS, et al. The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression. Int J Environ Res Public Health. 2018;15(8). LiangEF LimSZ TamWW HoCS ZhangMW McIntyreRS The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression Int J Environ Res Public Health 2018 15 8 Search in Google Scholar

33. Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs. 2017;31(3):199–215. HennissenL BakkerMJ BanaschewskiT CarucciS CoghillD DanckaertsM Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine CNS Drugs 2017 31 3 199 215 Search in Google Scholar

34. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–83. HabelLA CooperWO SoxCM ChanKA FiremanBH ArbogastPG ADHD medications and risk of serious cardiovascular events in young and middle-aged adults JAMA 2011 306 24 2673 83 Search in Google Scholar

35. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–904. CooperWO HabelLA SoxCM ChanKA ArbogastPG CheethamTC ADHD drugs and serious cardiovascular events in children and young adults N Engl J Med 2011 365 20 1896 904 Search in Google Scholar

36. Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psychiatry. 2019;28(10):1283–93. LiuH FengW ZhangD Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis Eur Child Adolesc Psychiatry 2019 28 10 1283 93 Search in Google Scholar

37. Chen Q, Hartman CA, Haavik J, Harro J, Klungsoyr K, Hegvik TA, et al. Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study. PLoS One. 2018;13(9):e0204516. ChenQ HartmanCA HaavikJ HarroJ KlungsoyrK HegvikTA Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study PLoS One 2018 13 9 e0204516 Search in Google Scholar

38. Humphreys KL, Eng T, Lee SS. Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry. 2013;70(7):740–9. HumphreysKL EngT LeeSS Stimulant medication and substance use outcomes: a meta-analysis JAMA Psychiatry 2013 70 7 740 9 Search in Google Scholar

39. Ahmed R, Aslani P. Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):791–815. AhmedR AslaniP Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults Expert Rev Pharmacoecon Outcomes Res 2013 13 6 791 815 Search in Google Scholar